All News
Physicians must perceive the patient as a person rather than a carrier of a disease disease - Eric Cassell. Check out this book, and other insights from @LCalabreseDO on patient/provider discordance #empathy #cleclinicrheum @HealioRheum @RheumNow https://t.co/f5jnUS701X
Cassandra Calabrese CCalabreseDO ( View Tweet)
#ACR20 @RheumNow https://t.co/0Kfe3Zforl
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
@SSNaushon MTX remains backbone of therapy given low cost, safety profile, and long experience with it. Majority of pts do well on MTX and do not require TNFi @Rheumnow.
Eric Dein ejdein1 ( View Tweet)
Interesting Swedish abstract 1997 at #ACR20. Adjuvant #herpeszoster vaccine (Shingrix) not effective for 25% of JAKi-treated RA pts (n=40) for antibody response (T cell response usually worse, not reported). Is better than nothing good enough? Maybe we need to hold JAKi briefly?
Jeffrey Curtis RADoctor ( View Tweet)
L06: Mavrilimumab in #GCA
⭐️Efficacy and safety of MAV maintaining sustained remission 26w new and relapsing/ref #GCA
Flare risk ➡️ 62% risk ⬇️ of flare w/ MAV
Sustained remission➡️ 33% ⬆️ in MAV
No diff in new or relapsing/ref pts,
No diff in AE
#ACR20 #ACRambassador
Sebastian E. Sattui MD, MS SattuiSEMD ( View Tweet)
Fantastic session about the 2020 guidelines for management of RA! Soon to be published.
One major difference from 2015 guidelines ➡️ Conditional recommendation to choose a Biologic over Triple Therapy in MTX-inadequate responders (Discussion about patient preference is key!) https://t.co/s016piIN7Q
Dr. Tina Mahajan drtinamahajan ( View Tweet)
SLR comparing the 4-dose ANCA #vasculitis (AAV) rituximab regimen (widely used in RCTs) to 2-dose #rheumatoidarthritis RTX regimen (common in clinical practice), to induce AAV remission, finds no difference in efficacy or safety.
Abs#2048 #ACR20 @RheumNow
https://t.co/WBaWN9d8vs
Mrinalini Dey DrMiniDey ( View Tweet)
.@LCalabreseDO from @ClevelandClinic is discussing the science of #empathy in #rheumatology at #ACR20.
How important is empathy in your doctor-patient relationship? https://t.co/xIdPWmc7UV
CreakyJoints.org CreakyJoints ( View Tweet)
Results of the FAST trial presented at #ACR20
- Safety study required by the EMA
- Febuxostat non-inferior to allopurinol for any outcomes
- Long-term use of febuxostat is not associated with an increased risk of death
Published in @TheLancet today https://t.co/EvJGPpDCR8
Links:
NatRevRheumatol NatRevRheumatol ( View Tweet)
Dr MacDonald presents Febuxostat versus Allopurinol Streamlined Trial. 6128 patients. HR 0·89 [95% CI 0·75-1·06] for cardiovascular events in febuxostat vs allopurinol. Mortality 7.2% vs 8.6%. Reassuring re cardiovascular safety of febuxostat @rheumnow #ACR20 Abstr#L08 #ACRbest
Richard Conway RichardPAConway ( View Tweet)
A new (better) approach to #rheumatic disease treatment has to include wellness, lifestyle, and beyond. And this includes #empathy, says @LCalabreseDO at #ACR20. https://t.co/paE1Io6uvC
CreakyJoints.org CreakyJoints ( View Tweet)
With Phase 2 of the Accelerating Medicines Partnership study of SLE underway, an #ACR20 session featured a panel that reviewed the methods being used to generate data & discussed some of the findings. Read the recap → https://t.co/hTnCdfBn10
American College of Rheumatology ACRheum ( View Tweet)
Just watched David Beck’s talk on somatic mutations in VEXAS. Genotyping to link phenotypically diverse disease. Such an exciting strategy to identify additional unknown diseases!!! #ACR https://t.co/gU9HEZyjRP
Adam J Brown AdamJBrownMD ( View Tweet)
FAST trial (Plenary) showed opposite of CAREs study. Febuxostat vs PBO in 6128 Gout pts, showed little dropout (~6%) in a 4 year study. Febuxostat (mean 81mg) had similar, flare rates, MACE/cardiac endpoints and CV death vs allopurinol #ACR20 Abstr#L08 https://t.co/FkdDtPB4Oi https://t.co/J9KonQHpT2
Dr. John Cush RheumNow ( View Tweet)
Listen to part II of our #ACR20 Day 3 recap. Follow the link below or find us on Apple podcasts.
https://t.co/1TcXfU5TMg https://t.co/evGkn9UARB
Links:
Dr. John Cush RheumNow ( View Tweet)
Upadacitinib vs. Adalimumab vs. PBO in PsA Phase 3 RCT ⬇️MSK symptoms, PsO, function, pain, fatigue, rads progression in UPA *⃣UPA15 non-inferior to ADA for ACR20, UPA30 superior *⃣Similar VTE in all arms @RheumNow #ACR20 Abs#2026 https://t.co/OHzIjXKqAu
Robert B Chao, MD doctorRBC ( View Tweet)
Does IL-6 blockade prevent mechanical ventilation or death in #COVID19? MGH study by Dr. Stone Abst#L07 graph shows no benefit @RheumNow #ACR20 https://t.co/DHfHYJCkod
Eric Dein ejdein1 ( View Tweet)
Patient-physician discordance seen in ~30% #rheumatoidarthritis patients starting #DMARDs
- ↑Patient-reported pain & functional impairment assoc. w/ discordance
- Patient-centric treatment discussions needed to reduce discordance
Abs#1978 #ACR20 @RheumNow
https://t.co/CdlHrBOdy0
Mrinalini Dey DrMiniDey ( View Tweet)
The avacopan story, stronger again:
(recall: avacopan targets C5aR)
endogenous anti-C5aR1 in GPA inversely correlates with dx activity, relapse
questions, via chair @philseo:
What happens to anti-C5aR1 with Rx?
Does this influence therapeutic strategy?
#ACR20 ABST2050 @RheumNow https://t.co/g4JfjQal8R
David Liew drdavidliew ( View Tweet)
Very strong push by #ACR20 to recc MTX in most RA patient scenarios including RA ILD, RA nodules, NAFLD in new RA guidance document @rheumnow
k dao KDAO2011 ( View Tweet)
